Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
-
Published:2024-03
Issue:
Volume:
Page:
-
ISSN:1071-9164
-
Container-title:Journal of Cardiac Failure
-
language:en
-
Short-container-title:Journal of Cardiac Failure
Author:
MASRI AHMADORCID, SHERRID MARK V., ABRAHAM THEODORE P., CHOUDHURY LUBNA, GARCIA-PAVIA PABLO, KRAMER CHRISTOPHER M., BARRIALES-VILLA ROBERTO, OWENS ANJALI T., RADER FLORIAN, NAGUEH SHERIF F., OLIVOTTO IACOPO, SABERI SARA, TOWER-RADER ALBREE, WONG TIMOTHY C., COATS CAROLINE J., WATKINS HUGH, FIFER MICHAEL A., SOLOMON SCOTT D., HEITNER STEPHEN B., JACOBY DANIEL L., KUPFER STUART, MALIK FADY I., MENG LISA, SOHN REGINA L., WOHLTMAN AMY, MARON MARTIN S.
Reference23 articles.
1. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction;Maron;Circulation,2006 2. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive Summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Ommen;J Am Coll Cardiol,2020 3. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial;Olivotto;Lancet,2020 4. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy;Desai;J Am Coll Cardiol,2022 5. Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy;Lu;J Am Heart Assoc,2018
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|